{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:50:12Z","timestamp":1794469812270,"version":"4.9.1"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T cell therapy is emerging as a promising approach for B cell-driven neurological autoimmune disorders, particularly those characterized by pathogenic autoantibodies that target key neural structures. These conditions, including neuromyelitis optica spectrum disorder, myasthenia gravis, Lambert-Eaton myasthenic syndrome, MOG antibody-associated disease, anti-NMDA receptor encephalitis, Diacylglycerol lipase alpha antibody associated encephalitis, stiff person syndrome, and multiple sclerosis, can be categorized based on their primary autoantigens into (1) extracellular antigen-associated (e.g., AQP4, AChR, NMDAR, MOG, VGCC), (2) intracellular antigen-associated (e.g., GAD65, DAGLA), or (3) unidentified antigenic origin (as seen in multiple sclerosis). This distinction is essential for guiding therapeutic strategies and exploring novel principles represented in distinct treatment approaches and their corresponding therapeutic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>In this review, we propose a classification of CAR T cell therapies designed for different target antigens, including: CD19\/20\/BCMA-directed CAR T cells targeting general B cell-mediated pathogenesis, regulatory T cells modified with CARs, and the design of chimeric autoantibody receptors (CAARs) to selectively deplete pathogenic B cells directly associated with disease progression while preserving immune tolerance. We further discuss preclinical and clinical advancements, key challenges such as safety concerns and neurotoxicity, and the future landscape of CAR T applications in neuromyelitis optica spectrum disorder, myasthenia gravis, Lambert-Eaton myasthenic syndrome, MOG antibody-associated disease, anti-NMDA receptor encephalitis, Diacylglycerol lipase alpha antibody associated encephalitis, stiff person syndrome, and multiple sclerosis according to the latest research, case and trial data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAR T cell therapy potentially offers a highly specific and effective method with thorough elimination of autoreactive B cells, representing a rapidly evolving field with the potential to transform the treatment of autoimmune neurological disorders. As CAR T technology advances, it holds the potential to become a groundbreaking immunoablative strategy with so-far disclosed controllable side effects; however, further long-term follow-up data are still needed to validate its application in autoimmune disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-025-03662-6","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:44:32Z","timestamp":1773294272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy"],"prefix":"10.1186","volume":"23","author":[{"given":"Muzi","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Y.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruogu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"8","key":"3662_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","volume":"19","author":"DS Pisetsky","year":"2023","unstructured":"Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023;19(8):509\u201324.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"3662_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/acn3.51492","volume":"9","author":"E Cort\u00e9s-Vicente","year":"2022","unstructured":"Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Pla-Junca F, Rojas-Garcia R, Paradas C, Sevilla T, et al. Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol. 2022;9(2):122\u201331.","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"3662_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in Aquaporin-4-Positive neuromyelitis Optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med"},{"issue":"11","key":"3662_CR4","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis Optica spectrum disorders: A systematic review and Meta-analysis. JAMA Neurol. 2016;73(11):1342\u20138.","journal-title":"JAMA Neurol"},{"issue":"7","key":"3662_CR5","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.4049\/jimmunol.154.7.3173","volume":"154","author":"K Ohishi","year":"1995","unstructured":"Ohishi K, Kanoh M, Shinomiya H, Hitsumoto Y, Utsumi S. Complement activation by cross-linked B cell-membrane IgM. J Immunol. 1995;154(7):3173\u20139.","journal-title":"J Immunol"},{"issue":"4","key":"3662_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMcibr2032177","volume":"384","author":"SS Zamvil","year":"2021","unstructured":"Zamvil SS, Hauser SL. Antigen presentation by B cells in multiple sclerosis. N Engl J Med. 2021;384(4):378\u201381.","journal-title":"N Engl J Med"},{"issue":"8","key":"3662_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41577-021-00652-6","volume":"22","author":"RW Jain","year":"2022","unstructured":"Jain RW, Yong VW. B cells in central nervous system disease: diversity, locations and pathophysiology. Nat Rev Immunol. 2022;22(8):513\u201324.","journal-title":"Nat Rev Immunol"},{"key":"3662_CR8","doi-asserted-by":"crossref","unstructured":"Koneczny I, Herbst R. Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells. 2019;8(7):671.","DOI":"10.3390\/cells8070671"},{"key":"3662_CR9","doi-asserted-by":"crossref","unstructured":"Morshed SA, Davies TF. Graves\u2019 disease mechanisms: the role of Stimulating, Blocking, and cleavage region TSH receptor antibodies. Hormone Metabolic Res = Hormon- Und Stoffwechselforschung = Horm Et Metab. 2015;47(10):727\u201334.","DOI":"10.1055\/s-0035-1559633"},{"key":"3662_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","volume":"11","author":"CM Hammers","year":"2016","unstructured":"Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016;11:175\u201397.","journal-title":"Annu Rev Pathol"},{"issue":"10206","key":"3662_CR11","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis Optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"issue":"4","key":"3662_CR12","doi-asserted-by":"publisher","first-page":"e200395","DOI":"10.1212\/NXI.0000000000200395","volume":"12","author":"N Seery","year":"2025","unstructured":"Seery N, Wesselingh R, Beech P, McLaughlin L, Rushen T, Halliday AJ, et al. Rituximab use for relapse prevention in Anti-NMDAR Antibody-Mediated encephalitis: A multicenter cohort study. Neurol Neuroimmunol Neuroinflamm. 2025;12(4):e200395.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3662_CR13","doi-asserted-by":"crossref","unstructured":"von Baumgarten L, Stauss HJ, L\u00fcnemann JD. Synthetic Cell-Based Immunotherapies for Neurologic Diseases. Neurology(R) neuroimmunology & neuroinflammation. 2023;10(5):e200139.","DOI":"10.1212\/NXI.0000000000200139"},{"issue":"20","key":"3662_CR14","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","volume":"5","author":"T Siddiqi","year":"2021","unstructured":"Siddiqi T, Wang X, Blanchard MS, Wagner JR, Popplewell LL, Budde LE, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021;5(20):4059\u201363.","journal-title":"Blood Adv"},{"issue":"39","key":"3662_CR15","doi-asserted-by":"publisher","first-page":"9773","DOI":"10.1073\/pnas.1810470115","volume":"115","author":"D H\u00e4usler","year":"2018","unstructured":"H\u00e4usler D, H\u00e4usser-Kinzel S, Feldmann L, Torke S, Lepennetier G, Bernard CCA, et al. Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proc Natl Acad Sci U S A. 2018;115(39):9773\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3662_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00415-025-13118-9","volume":"272","author":"S Cao","year":"2025","unstructured":"Cao S, Zhou X, Du J, Zhang J, Zhu Y, Wei L, et al. Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD. J Neurol. 2025;272(6):406.","journal-title":"J Neurol"},{"issue":"3","key":"3662_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"775","key":"3662_CR18","doi-asserted-by":"publisher","first-page":"eadl1666","DOI":"10.1126\/scitranslmed.adl1666","volume":"16","author":"P Danaher","year":"2024","unstructured":"Danaher P, Hasle N, Nguyen ED, Roberts JE, Rosenwasser N, Rickert C, et al. Childhood-onset lupus nephritis is characterized by complex interactions between kidney stroma and infiltrating immune cells. Sci Transl Med. 2024;16(775):eadl1666.","journal-title":"Sci Transl Med"},{"issue":"10416","key":"3662_CR19","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet (London England). 2023;402(10416):2034\u201344.","journal-title":"Lancet (London England)"},{"issue":"6","key":"3662_CR20","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"3662_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-Cell therapy in autoimmune Disease - A case series with Follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"3662_CR22","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1182\/blood-2018-99-119031","volume":"132","author":"JL Koff","year":"2018","unstructured":"Koff JL, Cashman KS, Warren V, Smith K, Flowers CR, Sanz I. Circulating B cell subsets from untreated diffuse large B cell lymphoma (DLBCL) patients resemble those of patients with autoimmune disease. Blood. 2018;132(Supplement 1):4221.","journal-title":"Blood"},{"issue":"5","key":"3662_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40291-024-00730-0","volume":"28","author":"AC Pecher","year":"2024","unstructured":"Pecher AC, Hensen L, Lengerke C, Henes J. The future of CAR T therapeutics to treat autoimmune disorders. Mol Diagn Ther. 2024;28(5):593\u2013600.","journal-title":"Mol Diagn Ther"},{"issue":"7","key":"3662_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, Miljkovi\u0107 MD, Chahin N, Sahagian G, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia Gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 2023;22(7):578\u201390.","journal-title":"Lancet Neurol"},{"issue":"12","key":"3662_CR25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, B\u00f6ttcher M, Desel C, Borie D, et al. Anti-CD19 CAR T cells for refractory myasthenia Gravis. Lancet Neurol. 2023;22(12):1104\u20135.","journal-title":"Lancet Neurol"},{"issue":"11","key":"3662_CR26","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","volume":"112","author":"J Motte","year":"2024","unstructured":"Motte J, Sgodzai M, Schneider-Gold C, Steckel N, Mika T, Hegelmaier T, et al. Treatment of concomitant myasthenia Gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells. Neuron. 2024;112(11):1757\u2013e632.","journal-title":"Neuron"},{"issue":"95","key":"3662_CR27","doi-asserted-by":"publisher","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","volume":"9","author":"C Qin","year":"2024","unstructured":"Qin C, Zhang M, Mou DP, Zhou LQ, Dong MH, Huang L, et al. Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity. Sci Immunol. 2024;9(95):eadj9730.","journal-title":"Sci Immunol"},{"issue":"1","key":"3662_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin C, Tian DS, Zhou LQ, Shang K, Huang L, Dong MH, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis Optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8(1):5.","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"3662_CR29","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","volume":"186","author":"SM Reincke","year":"2023","unstructured":"Reincke SM, von Wardenburg N, Homeyer MA, Kornau HC, Spagni G, Li LY, et al. Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell. 2023;186(23):5084\u2013e9718.","journal-title":"Cell"},{"issue":"2","key":"3662_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 2005;62(2):258\u201364.","journal-title":"Arch Neurol"},{"issue":"3","key":"3662_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","volume":"128","author":"VG Bhoj","year":"2016","unstructured":"Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016;128(3):360\u201370.","journal-title":"Blood"},{"issue":"1","key":"3662_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","volume":"43","author":"JL Halliley","year":"2015","unstructured":"Halliley JL, Tipton CM, Liesveld J, Rosenberg AF, Darce J, Gregoretti IV, et al. Long-Lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity. 2015;43(1):132\u201345.","journal-title":"Immunity"},{"key":"3662_CR33","first-page":"497","volume-title":"CD19 chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, M\u00fcller F, Yalcin Mutlu M, V\u00f6lkl S, Aigner M, Bozec A, et al. CD19 chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus. Volume 76. Hoboken, NJ: Arthritis & rheumatology; 2024. pp. 497\u2013504. 4."},{"issue":"11","key":"3662_CR34","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/d41573-023-00166-x","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. CAR T cell therapies Raise hopes - and questions - for lupus and autoimmune disease. Nat Rev Drug Discov. 2023;22(11):859\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"3662_CR35","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","volume":"28","author":"SJ Grant","year":"2022","unstructured":"Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, et al. Clinical Presentation, risk Factors, and outcomes of immune effector cell-Associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: A systematic review. Transplantation Cell Therapy. 2022;28(6):294\u2013302.","journal-title":"Transplantation Cell Therapy"},{"issue":"10","key":"3662_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","volume":"18","author":"LMR Ferreira","year":"2019","unstructured":"Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Next-generation regulatory T cell therapy. Nat Rev Drug Discov. 2019;18(10):749\u201369.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"3662_CR37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757\u201368.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"3662_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","volume":"23","author":"F Ram\u00edrez-Valle","year":"2024","unstructured":"Ram\u00edrez-Valle F, Maranville JC, Roy S, Plenge RM. Sequential immunotherapy: towards cures for autoimmunity. Nat Rev Drug Discov. 2024;23(7):501\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"3662_CR39","unstructured":"Thaler FS, Zimmermann L, Kammermeier S, Strippel C, Ringelstein M, Kraft A, et al. Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1088."},{"issue":"12","key":"3662_CR40","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr., Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of Eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia Gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"6","key":"3662_CR41","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, Berthele A, de S\u00e8ze J, Levy M, et al. Ravulizumab in Aquaporin-4-Positive neuromyelitis Optica spectrum disorder. Ann Neurol. 2023;93(6):1053\u201368.","journal-title":"Ann Neurol"},{"issue":"4","key":"3662_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","volume":"88","author":"F Scheibe","year":"2017","unstructured":"Scheibe F, Pr\u00fcss H, Mengel AM, Kohler S, N\u00fcmann A, K\u00f6hnlein M, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology. 2017;88(4):366\u201370.","journal-title":"Neurology"},{"issue":"4","key":"3662_CR43","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","volume":"13","author":"WJ Lee","year":"2016","unstructured":"Lee WJ, Lee ST, Moon J, Sunwoo JS, Byun JI, Lim JA, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016;13(4):824\u201332.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"3662_CR44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"2","key":"3662_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"C Tur","year":"2023","unstructured":"Tur C, Carbonell-Mirabent P, Cobo-Calvo \u00c1, Otero-Romero S, Arrambide G, Midaglia L, et al. Association of early progression independent of relapse activity with Long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 2023;80(2):151\u201360.","journal-title":"JAMA Neurol"},{"key":"3662_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mto.2016.23","volume":"3","author":"MV Maus","year":"2016","unstructured":"Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivi\u00e8re I, Merghoub T, et al. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol Therapy Oncolytics. 2016;3:1\u20139.","journal-title":"Mol Therapy Oncolytics"},{"issue":"1","key":"3662_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3662_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","volume":"4","author":"H Aghajanian","year":"2022","unstructured":"Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metabolism. 2022;4(2):163\u20139.","journal-title":"Nat Metabolism"},{"issue":"7949","key":"3662_CR49","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614(7949):635\u201348.","journal-title":"Nature"},{"issue":"1","key":"3662_CR50","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"issue":"4","key":"3662_CR51","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s11427-022-2212-5","volume":"66","author":"Y Sun","year":"2023","unstructured":"Sun Y, Yuan Y, Zhang B, Zhang X. CARs: a new approach for the treatment of autoimmune diseases. Sci China Life Sci. 2023;66(4):711\u201328.","journal-title":"Sci China Life Sci"},{"key":"3662_CR52","doi-asserted-by":"publisher","first-page":"603237","DOI":"10.3389\/fimmu.2020.603237","volume":"11","author":"M Sadeqi Nezhad","year":"2020","unstructured":"Sadeqi Nezhad M, Seifalian A, Bagheri N, Yaghoubi S, Karimi MH, Adbollahpour-Alitappeh M. Chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment? Front Immunol. 2020;11:603237.","journal-title":"Front Immunol"},{"issue":"35","key":"3662_CR53","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of Immune-Related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978\u201392.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3662_CR54","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"3662_CR55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","volume":"45","author":"L Kattamuri","year":"2025","unstructured":"Kattamuri L, Mohan Lal B, Vojjala N, Jain M, Sharma K, Jain S, et al. Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review. Rheumatol Int. 2025;45(1):18.","journal-title":"Rheumatol Int"},{"issue":"10","key":"3662_CR56","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219\u201326.","journal-title":"Cancer Discov"},{"issue":"9","key":"3662_CR57","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia Gravis with chimeric autoantibody receptor T cells. Nat Biotechnol. 2023;41(9):1229\u201338.","journal-title":"Nat Biotechnol"},{"issue":"7971","key":"3662_CR58","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315.","journal-title":"Nature"},{"issue":"12","key":"3662_CR59","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","volume":"21","author":"H Pr\u00fcss","year":"2021","unstructured":"Pr\u00fcss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021;21(12):798\u2013813.","journal-title":"Nat Rev Immunol"},{"key":"3662_CR60","doi-asserted-by":"publisher","first-page":"548469","DOI":"10.3389\/fimmu.2021.548469","volume":"12","author":"PD Burbelo","year":"2021","unstructured":"Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies targeting intracellular and extracellular proteins in autoimmunity. Front Immunol. 2021;12:548469.","journal-title":"Front Immunol"},{"issue":"3","key":"3662_CR61","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/WCO.0000000000001261","volume":"37","author":"Y Segal","year":"2024","unstructured":"Segal Y, Zekeridou A. Interest of rare autoantibodies in autoimmune encephalitis and paraneoplastic neurological syndromes: the utility (or futility) of rare antibody discovery. Curr Opin Neurol. 2024;37(3):295\u2013304.","journal-title":"Curr Opin Neurol"},{"issue":"20","key":"3662_CR62","doi-asserted-by":"publisher","first-page":"e1873","DOI":"10.1212\/WNL.0000000000008472","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, Jitprapaikulsan J, Bi H, Do Campo RV, McKeon A, Pittock SJ, et al. Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome. Neurology. 2019;93(20):e1873\u201380.","journal-title":"Neurology"},{"key":"3662_CR63","doi-asserted-by":"publisher","first-page":"120540","DOI":"10.1016\/j.jns.2022.120540","volume":"445","author":"M Madlener","year":"2023","unstructured":"Madlener M, Strippel C, Thaler FS, Doppler K, Wandinger KP, Lewerenz J, et al. Glutamic acid decarboxylase antibody-associated neurological syndromes: clinical and antibody characteristics and therapy response. J Neurol Sci. 2023;445:120540.","journal-title":"J Neurol Sci"},{"issue":"5","key":"3662_CR64","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ana.20269","volume":"56","author":"SJ Pittock","year":"2004","unstructured":"Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56(5):715\u20139.","journal-title":"Ann Neurol"},{"issue":"4","key":"3662_CR65","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","volume":"14","author":"B Hemmer","year":"2015","unstructured":"Hemmer B, Kerschensteiner M, Korn T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 2015;14(4):406\u201319.","journal-title":"Lancet Neurol"},{"issue":"9","key":"3662_CR66","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"3662_CR67","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","volume":"21","author":"JJ Verschuuren","year":"2022","unstructured":"Verschuuren JJ, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189\u2013202.","journal-title":"Lancet Neurol"},{"key":"3662_CR68","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia Gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212.","journal-title":"Front Immunol"},{"issue":"4","key":"3662_CR69","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","volume":"263","author":"S Binks","year":"2016","unstructured":"Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016;263(4):826\u201334.","journal-title":"J Neurol"},{"issue":"8","key":"3662_CR70","doi-asserted-by":"publisher","first-page":"104962","DOI":"10.1016\/j.jbc.2023.104962","volume":"299","author":"TM Uyen Dao","year":"2023","unstructured":"Uyen Dao TM, Barbeau S, Mess\u00e9ant J, Della-Gaspera B, Bouceba T, Semprez F, et al. The collagen ColQ binds to LRP4 and regulates the activation of the Muscle-Specific Kinase-LRP4 receptor complex by Agrin at the neuromuscular junction. J Biol Chem. 2023;299(8):104962.","journal-title":"J Biol Chem"},{"issue":"1","key":"3662_CR71","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/nyas.13562","volume":"1413","author":"M Marino","year":"2018","unstructured":"Marino M, Bartoccioni E, Alboini PE, Evoli A. Rituximab in myasthenia gravis: a to be or not to be inhibitor of T cell function. Ann N Y Acad Sci. 2018;1413(1):41\u20138.","journal-title":"Ann N Y Acad Sci"},{"key":"3662_CR72","doi-asserted-by":"crossref","unstructured":"Jiang R, Fichtner ML, Hoehn KB, Pham MC, Stathopoulos P, Nowak RJ, et al. Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia Gravis relapses. JCI Insight. 2020;5(14):e136471.","DOI":"10.1172\/jci.insight.136471"},{"issue":"5","key":"3662_CR73","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia Gravis. NEJM Evid. 2022;1(5):EVIDoa2100066.","journal-title":"NEJM Evid"},{"issue":"2","key":"3662_CR74","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024;20(2):84\u201398.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"3662_CR75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","volume":"38","author":"S Crisafulli","year":"2024","unstructured":"Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifir\u00f2 G, et al. Myasthenia Gravis treatment: from old drugs to innovative therapies with a glimpse into the future. CNS Drugs. 2024;38(1):15\u201332.","journal-title":"CNS Drugs"},{"issue":"22","key":"3662_CR76","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","volume":"332","author":"VA Lennon","year":"1995","unstructured":"Lennon VA, Kryzer TJ, Griesmann GE, O\u2019Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467\u201374.","journal-title":"N Engl J Med"},{"issue":"1","key":"3662_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","volume":"147","author":"M Motomura","year":"1997","unstructured":"Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147(1):35\u201342.","journal-title":"J Neurol Sci"},{"issue":"12","key":"3662_CR78","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098\u2013107.","journal-title":"Lancet Neurol"},{"issue":"7","key":"3662_CR79","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893\u2013902.","journal-title":"Eur J Neurol"},{"issue":"5","key":"3662_CR80","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475\u201390.","journal-title":"Lancet Neurol"},{"issue":"10","key":"3662_CR81","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis Optica. Neurology. 2006;66(10):1485\u20139.","journal-title":"Neurology"},{"issue":"12","key":"3662_CR82","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","volume":"17","author":"SJ Pittock","year":"2021","unstructured":"Pittock SJ, Zekeridou A, Weinshenker BG. Hope for patients with neuromyelitis Optica spectrum disorders - from mechanisms to trials. Nat Rev Neurol. 2021;17(12):759\u201373.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"3662_CR83","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1352458515587752","volume":"22","author":"IH Jeong","year":"2016","unstructured":"Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis Optica spectrum disorder using multifaceted endpoints. Mult Scler. 2016;22(3):329\u201339.","journal-title":"Mult Scler"},{"issue":"5","key":"3662_CR84","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis Optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402\u201312.","journal-title":"Lancet Neurol"},{"key":"3662_CR85","doi-asserted-by":"publisher","first-page":"102869","DOI":"10.1016\/j.msard.2021.102869","volume":"50","author":"M Velasco","year":"2021","unstructured":"Velasco M, Zarco LA, Agudelo-Arrieta M, Torres-Camacho I, Garcia-Cifuentes E, Mu\u00f1oz O. Effectiveness of treatments in neuromyelitis Optica to modify the course of disease in adult patients. Systematic review of literature. Mult Scler Relat Disord. 2021;50:102869.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"3662_CR86","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al. Safety and efficacy of Tocilizumab versus azathioprine in highly relapsing neuromyelitis Optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 2020;19(5):391\u2013401.","journal-title":"Lancet Neurol"},{"issue":"8","key":"3662_CR87","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1007\/s00415-023-11737-8","volume":"270","author":"A Al-Ani","year":"2023","unstructured":"Al-Ani A, Chen JJ, Costello F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current Understanding and challenges. J Neurol. 2023;270(8):4132\u201350.","journal-title":"J Neurol"},{"issue":"10","key":"3662_CR88","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2024.2811","volume":"81","author":"YN Kwon","year":"2024","unstructured":"Kwon YN, Kim B, Kim JS, Park KS, Seo DY, Kim H, et al. Time to treat first acute attack of Myelin oligodendrocyte glycoprotein Antibody-Associated disease. JAMA Neurol. 2024;81(10):1073\u201384.","journal-title":"JAMA Neurol"},{"issue":"5","key":"3662_CR89","doi-asserted-by":"publisher","first-page":"e200292","DOI":"10.1212\/NXI.0000000000200292","volume":"11","author":"JM Cabrera-Maqueda","year":"2024","unstructured":"Cabrera-Maqueda JM, Sepulveda M, Garc\u00eda RR, Mu\u00f1oz-S\u00e1nchez G, Mart\u00ednez-Cibrian N, Ort\u00edz-Maldonado V, et al. CD19-Directed CAR T-Cells in a patient with refractory MOGAD: clinical and Immunologic Follow-Up for 1 year. Neurol Neuroimmunol Neuroinflamm. 2024;11(5):e200292.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"3662_CR90","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","volume":"7","author":"J Dalmau","year":"2008","unstructured":"Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091\u20138.","journal-title":"Lancet Neurol"},{"issue":"12","key":"3662_CR91","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.1172\/JCI138416","volume":"130","author":"J Lee","year":"2020","unstructured":"Lee J, Lundgren DK, Mao X, Manfredo-Vieira S, Nunez-Cruz S, Williams EF, et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest. 2020;130(12):6317\u201324.","journal-title":"J Clin Invest"},{"key":"3662_CR92","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","volume":"96","author":"L Zhang","year":"2019","unstructured":"Zhang L, Sosinowski T, Cox AR, Cepeda JR, Sekhar NS, Hartig SM, et al. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class ii:peptide complex modulate the progression of autoimmune diabetes. J Autoimmun. 2019;96:50\u20138.","journal-title":"J Autoimmun"},{"key":"3662_CR93","doi-asserted-by":"publisher","first-page":"1207108","DOI":"10.3389\/fimmu.2023.1207108","volume":"14","author":"N Obarorakpor","year":"2023","unstructured":"Obarorakpor N, Patel D, Boyarov R, Amarsaikhan N, Cepeda JR, Eastes D, et al. Regulatory T cells targeting a pathogenic MHC class II: insulin peptide epitope postpone spontaneous autoimmune diabetes. Front Immunol. 2023;14:1207108.","journal-title":"Front Immunol"},{"key":"3662_CR94","doi-asserted-by":"publisher","first-page":"577915","DOI":"10.1016\/j.jneuroim.2022.577915","volume":"369","author":"SD Newsome","year":"2022","unstructured":"Newsome SD, Johnson T. Stiff person syndrome spectrum disorders; more than Meets the eye. J Neuroimmunol. 2022;369:577915.","journal-title":"J Neuroimmunol"},{"issue":"Pt 2","key":"3662_CR95","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/brain\/awv324","volume":"139","author":"C Werner","year":"2016","unstructured":"Werner C, Pauli M, Doose S, Weishaupt A, Haselmann H, Gr\u00fcnewald B, et al. Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain. 2016;139(Pt 2):365\u201379.","journal-title":"Brain"},{"issue":"10","key":"3662_CR96","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41582-024-01012-3","volume":"20","author":"MC Dalakas","year":"2024","unstructured":"Dalakas MC. Stiff-person syndrome and related disorders - diagnosis, mechanisms and therapies. Nat Rev Neurol. 2024;20(10):587\u2013601.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"3662_CR97","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/practneurol-2011-000071","volume":"11","author":"S Hadavi","year":"2011","unstructured":"Hadavi S, Noyce AJ, Leslie RD, Giovannoni G. Stiff person syndrome. Pract Neurol. 2011;11(5):272\u201382.","journal-title":"Pract Neurol"},{"issue":"7","key":"3662_CR98","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/acn3.51791","volume":"10","author":"NH Chia","year":"2023","unstructured":"Chia NH, McKeon A, Dalakas MC, Flanagan EP, Bower JH, Klassen BT, et al. Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria. Ann Clin Transl Neurol. 2023;10(7):1083\u201394.","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"3662_CR99","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/archneur.61.6.902","volume":"61","author":"G Rakocevic","year":"2004","unstructured":"Rakocevic G, Raju R, Dalakas MC. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol. 2004;61(6):902\u20134.","journal-title":"Arch Neurol"},{"issue":"3","key":"3662_CR100","doi-asserted-by":"publisher","first-page":"e0121364","DOI":"10.1371\/journal.pone.0121364","volume":"10","author":"N Gresa-Arribas","year":"2015","unstructured":"Gresa-Arribas N, Ari\u00f1o H, Mart\u00ednez-Hern\u00e1ndez E, Petit-Pedrol M, Sabater L, Saiz A, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS ONE. 2015;10(3):e0121364.","journal-title":"PLoS ONE"},{"issue":"26","key":"3662_CR101","doi-asserted-by":"publisher","first-page":"e2403227121","DOI":"10.1073\/pnas.2403227121","volume":"121","author":"S Faissner","year":"2024","unstructured":"Faissner S, Motte J, Sgodzai M, Geis C, Haghikia A, Mougiakakos D, et al. Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proc Natl Acad Sci U S A. 2024;121(26):e2403227121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"3662_CR102","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/jnnp-2024-333458","volume":"95","author":"R Miske","year":"2024","unstructured":"Miske R, Scharf M, Borowski K, Specht I, Corty M, Loritz MJ, et al. Identification of DAGLA as an autoantibody target in cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2024;95(11):1064\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"18","key":"3662_CR103","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1523\/JNEUROSCI.0054-06.2006","volume":"26","author":"T Yoshida","year":"2006","unstructured":"Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M, et al. Localization of Diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J Neurosci. 2006;26(18):4740\u201351.","journal-title":"J Neurosci"},{"issue":"7","key":"3662_CR104","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s00415-025-13197-8","volume":"272","author":"N Vorasoot","year":"2025","unstructured":"Vorasoot N, Isitan-Alkawadri C, Pillai B, Miske R, Dubey D, Gilligan M, et al. DAGLA autoantibody experience at Mayo clinic. J Neurol. 2025;272(7):460.","journal-title":"J Neurol"},{"issue":"9","key":"3662_CR105","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.medj.2025.100776","volume":"6","author":"T Hegelmaier","year":"2025","unstructured":"Hegelmaier T, Wolleschak D, Pappa V, Wickel J, Geis C, Miske R, et al. Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis. Med. 2025;6(9):100776.","journal-title":"Med"},{"issue":"12","key":"3662_CR106","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: A review. Am J Med. 2020;133(12):1380\u2013e902.","journal-title":"Am J Med"},{"issue":"10076","key":"3662_CR107","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S0140-6736(16)30959-X","volume":"389","author":"WJ Brownlee","year":"2017","unstructured":"Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet (London England). 2017;389(10076):1336\u201346.","journal-title":"Lancet (London England)"},{"issue":"4","key":"3662_CR108","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","volume":"80","author":"BA Cree","year":"2016","unstructured":"Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80(4):499\u2013510.","journal-title":"Ann Neurol"},{"issue":"1","key":"3662_CR109","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41582-019-0268-z","volume":"16","author":"JD L\u00fcnemann","year":"2020","unstructured":"L\u00fcnemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol. 2020;16(1):56\u201362.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"3662_CR110","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PA. B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021;17(7):399\u2013414.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"3662_CR111","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","volume":"80","author":"T Kalincik","year":"2023","unstructured":"Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, et al. Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active Relapsing-Remitting multiple sclerosis. JAMA Neurol. 2023;80(7):702\u201313.","journal-title":"JAMA Neurol"},{"key":"3662_CR112","doi-asserted-by":"crossref","unstructured":"Greenfield AL, Dandekar R, Ramesh A, Eggers EL, Wu H, Laurent S, et al. Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis. JCI Insight. 2019;4(6):e126599.","DOI":"10.1172\/jci.insight.126599"},{"key":"3662_CR113","doi-asserted-by":"publisher","first-page":"104465","DOI":"10.1016\/j.ebiom.2023.104465","volume":"89","author":"L Bogers","year":"2023","unstructured":"Bogers L, Engelenburg HJ, Janssen M, Unger PA, Melief MJ, Wierenga-Wolf AF, et al. Selective emergence of antibody-secreting cells in the multiple sclerosis brain. EBioMedicine. 2023;89:104465.","journal-title":"EBioMedicine"},{"key":"3662_CR114","doi-asserted-by":"crossref","unstructured":"Gupta S, Simic M, Sagan SA, Shepherd C, Duecker J, Sobel RA, et al. CAR-T Cell-Mediated B-Cell depletion in central nervous system autoimmunity. Neurology(R) Neuroimmunol Neuroinflammation. 2023;10(2):e200080.","DOI":"10.1212\/NXI.0000000000200080"},{"issue":"6","key":"3662_CR115","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/brain\/awab093","volume":"144","author":"M Mitsdoerffer","year":"2021","unstructured":"Mitsdoerffer M, Di Liberto G, D\u00f6tsch S, Sie C, Wagner I, Pfaller M, et al. Formation and Immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity. Brain. 2021;144(6):1697\u2013710.","journal-title":"Brain"},{"issue":"6","key":"3662_CR116","first-page":"550","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med (New York NY). 2024;5(6):550\u2013e82.","journal-title":"Med (New York NY)"},{"issue":"1","key":"3662_CR117","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/ni.1818","volume":"11","author":"K Wing","year":"2010","unstructured":"Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11(1):7\u201313.","journal-title":"Nat Immunol"},{"key":"3662_CR118","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","volume":"9","author":"M Fransson","year":"2012","unstructured":"Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, et al. CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation. 2012;9:112.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"3662_CR119","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/ana.27029","volume":"96","author":"G Brittain","year":"2024","unstructured":"Brittain G, Roldan E, Alexander T, Saccardi R, Snowden JA, Sharrack B, et al. The role of chimeric antigen receptor T-Cell therapy in Immune-Mediated neurological diseases. Ann Neurol. 2024;96(3):441\u201352.","journal-title":"Ann Neurol"},{"issue":"6","key":"3662_CR120","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","volume":"23","author":"A Haghikia","year":"2024","unstructured":"Haghikia A, Schett G, Mougiakakos D. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. Lancet Neurol. 2024;23(6):615\u201324.","journal-title":"Lancet Neurol"},{"issue":"2","key":"3662_CR121","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","volume":"80","author":"B Zhang","year":"2021","unstructured":"Zhang B, Wang Y, Yuan Y, Sun J, Liu L, Huang D, et al. In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells. Ann Rheum Dis. 2021;80(2):176\u201384.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3662_CR122","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann C, M\u00fcller F, Distler JHW, Gy\u00f6rfi AH, V\u00f6lkl S, Aigner M, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023;82(8):1117\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"3662_CR123","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023;329(24):2154\u201362.","journal-title":"JAMA"},{"key":"3662_CR124","doi-asserted-by":"crossref","unstructured":"Cui Y, David M, Bouchareychas L, Rouquier S, Sajuthi S, Ayrault M, et al. IL23R-specific CAR Tregs for the treatment of Crohn\u2019s disease. Journal of Crohn\u2019s & colitis; 2024.","DOI":"10.1093\/ecco-jcc\/jjae135"},{"key":"3662_CR125","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","volume":"103","author":"M Tenspolde","year":"2019","unstructured":"Tenspolde M, Zimmermann K, Weber LC, Hapke M, Lieber M, Dywicki J, et al. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun. 2019;103:102289.","journal-title":"J Autoimmun"},{"key":"3662_CR126","doi-asserted-by":"crossref","unstructured":"Dawson NAJ, Rosado-S\u00e1nchez I, Novakovsky GE, Fung VCW, Huang Q, McIver E, et al. Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells. Sci Transl Med. 2020;12(557):eaaz3866.","DOI":"10.1126\/scitranslmed.aaz3866"},{"key":"3662_CR127","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3389\/fimmu.2017.01313","volume":"8","author":"WI Yeh","year":"2017","unstructured":"Yeh WI, Seay HR, Newby B, Posgai AL, Moniz FB, Michels A, et al. Avidity and bystander suppressive capacity of human regulatory T cells expressing de Novo autoreactive T-Cell receptors in type 1 diabetes. Front Immunol. 2017;8:1313.","journal-title":"Front Immunol"},{"key":"3662_CR128","doi-asserted-by":"publisher","first-page":"581433","DOI":"10.3389\/fimmu.2020.581433","volume":"11","author":"Z Mukhatayev","year":"2020","unstructured":"Mukhatayev Z, Dellacecca ER, Cosgrove C, Shivde R, Jaishankar D, Pontarolo-Maag K, et al. Antigen specificity enhances disease control by Tregs in vitiligo. Front Immunol. 2020;11:581433.","journal-title":"Front Immunol"},{"issue":"3","key":"3662_CR129","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin C, Vo LT, Bluestone JA. T(reg) cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20(3):158\u201372.","journal-title":"Nat Rev Immunol"},{"key":"3662_CR130","doi-asserted-by":"publisher","first-page":"104224","DOI":"10.1016\/j.cellimm.2020.104224","volume":"358","author":"IA Radichev","year":"2020","unstructured":"Radichev IA, Yoon J, Scott DW, Griffin K, Savinov AY. Towards antigen-specific Tregs for type 1 diabetes: construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor. Cell Immunol. 2020;358:104224.","journal-title":"Cell Immunol"},{"key":"3662_CR131","doi-asserted-by":"crossref","unstructured":"Imam, Shahnawaz and Dar, Pervaiz and Alfonso-Jaume, Maria and Al-Khudhair, Ahmed and Jaume, Juan Carlos. Spontaneous Type-1-Diabetes Humanized Transgenics Help Unveil Pathophysiology of Human Diabetes and Allow for Disease-Reverting CAR-Treg Immunotherapy. CR-MEDICINE-D-21-00036. Available at SSRN: https:\/\/ssrn.com\/abstract=3778362 or http:\/\/dx.doi.org\/10.2139\/ssrn.3778362.","DOI":"10.2139\/ssrn.3778362"},{"issue":"1","key":"3662_CR132","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaneurol.2024.3818","volume":"82","author":"FS Ismail","year":"2025","unstructured":"Ismail FS, Gallus M, Meuth SG, Okada H, Hartung HP, Melzer N. Current and future roles of chimeric antigen receptor T-Cell therapy in neurology: A review. JAMA Neurol. 2025;82(1):93\u2013103.","journal-title":"JAMA Neurol"},{"key":"3662_CR133","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1172\/jci.insight.94263","volume":"2","author":"P Stathopoulos","year":"2017","unstructured":"Stathopoulos P, Kumar A, Nowak RJ, O\u2019Connor KC. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia Gravis. JCI Insight. 2017;2:17.","journal-title":"JCI Insight"},{"issue":"Supplement 1","key":"3662_CR134","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1182\/blood-2023-188830","volume":"142","author":"F Mueller","year":"2023","unstructured":"Mueller F, Schwingen NR, Stabel L, Aigner M, Taubmann J, Kretschmann S, et al. CAR-T cell therapy in patients with refractory systemic autoimmune diseases exhibits less Inflammation, toxicities and different cellular dynamics compared to patients with B cell lymphoma. Blood. 2023;142(Supplement 1):6871.","journal-title":"Blood"},{"issue":"1","key":"3662_CR135","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41591-023-02716-7","volume":"30","author":"C Arnold","year":"2024","unstructured":"Arnold C. Autoimmune disease is the next frontier for CAR T cell therapy. Nat Med. 2024;30(1):6\u20139.","journal-title":"Nat Med"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03662-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03662-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03662-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:02:32Z","timestamp":1780300952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-025-03662-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3662"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03662-6","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding details has been updated","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}